natgillin/translations-raw huggingface dataset:
Behandling med Zometa bør genoptages med den samme dosis som blev givet før afbrydelse af behandlingen.
Zometa treatment should be resumed at the same dose as that given prior to treatment interruption.
Behandling med Zydelig bør udføres af en læge med erfaring i anvendelsen af anticancerbehandling.
Treatment with Zydelig should be conducted by a physician experienced in the use of anticancer therapies.
Behandling med Zyllt kan påbegyndes få dage efter anfaldet og indtil 35 dage efter patienter, der for nyligt har haft et iskæmisk slagtilfælde (et slagtilfælde forårsaget af manglende blodforsyning til en del af hjernen).
Zyllt can be started between a few days and 35 days after the attack; patients who have had a recent ischaemic stroke (stroke caused by failure of the blood supply to part of the brain).
Behandling med β2-agonister kan give anledning til en stigning af insulin, frie fedtsyrer, glycerol og ketonstoffer i blodet.
Treatment with β2 adrenoceptor agonists may result in an increase in blood levels of insulin, free fatty acids, glycerol and ketone bodies.
Behandling mod bidende lus (Felicola subrostratus)
Treatment of biting lice infestations (Felicola subrostratus)
Behandling mod bidende lus (katte og hunde) Der behandles én gang med veterinærlægemidlet.
Treatment of biting lice (cats and dogs)
Behandling mod bidende lus (Trichodectes canis)
Treatment of biting lice infestations (Trichodectes canis)
Behandling mod hageorm (katte)
Treatment of hookworm infections (cats)
Behandling mod sarkoptesskab (forårsaget af Sarcoptes scabiei)
Treatment of sarcoptic mange (caused by Sarcoptes scabiei)
Behandling mod spolorm (katte og hunde) Der behandles én gang med veterinærlægemidlet.
Treatment of roundworm infections (cats and dogs)
Behandling mod tuberkulose skal overvejes inden start af Cosentyx hos patienter med latent tuberkulose.
Anti-tuberculosis therapy should be considered prior to initiation of Cosentyx in patients with latent tuberculosis.
Behandling mod voksne hageorm (Ancylostoma tubaeforme).
Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Behandling mod voksne intestinale hageorm (Ancylostoma tubaeforme).
Treatment of adult intestinal hookworms (Ancylostoma tubaeforme).
Behandling mod voksne rundorme (Toxocara cati)
Treatment of adult roundworms (Toxocara cati)
Behandling mod voksne spolorm (Toxocara canis).
Treatment of adult intestinal roundworms (Toxocara canis).
Behandling mod voksne spolorm (Toxocara cati)
Treatment of adult roundworms (Toxocara cati)
Behandling mod voksne stadier af intestinale rundorme (Toxocara canis).
Treatment of adult intestinal roundworms (Toxocara canis).
Behandling mod øremider (0todectes cynotis)
Treatment of ear mites (Otodectes cynotis).
Behandling mod øremider (katte)
Treatment of ear mites (cats)
Behandling mod øremider (Otodectes cynotis).
Treatment of ear mites (Otodectes cynotis).
Behandling MP
Treatment
Behandling må ikke startes, hvis det absolutte neutrofiltal er < 1,5 109/l, hvis trombocyttallet er
Treatment must not be started if the absolute neutrophil count is < 1.5 109/L, if the platelet counts are
Behandling og forebyggelse af
Treatment and
Behandling og forebyggelse af angioødem-anfald inden indgreb hos voksne og unge i alderen 12 til 17 år med hereditært angioødem (HAE).
Treatment and pre-procedure prevention of angioedema attacks in adults and adolescents 12 to 17 years old with hereditary angioedema (HAE).
Behandling og forebyggelse af flåtangreb (Ixodes ricinus).
Treatment and prevention of infestations by ticks (Ixodes ricinus).
Behandling og forebyggelse af flåtangreb (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica,Haemaphysalis. longicornis, Amblyomma americanum og Amblyomma maculatum) og loppeangreb (Ctenocephalides felis og Ctenocephalides canis) hos hund.
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis).
Behandling og forebyggelse af loppe- og flåtangreb.
Treatment and prevention of infestations with fleas and ticks.
Behandling og forebyggelse af loppeangreb (Ctenocephalides canis og C. felis).
Treatment and prevention of flea infestation (Ctenocephalides canis and C. felis.).
Behandling og forebyggelse af loppeangreb (Ctenocephalides felis).
Treatment and prevention of infestations by fleas (Ctenocephalides felis).
Behandling og forebyggelse af loppeinfestationer forårsaget af Ctenocephalides spp i en måned efter en enkelt behandling.
Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration.
Behandling og forebyggelse af loppeinfestationer, når samtidig forebyggelse af hjerteorm og/eller behandling af nematodeinfektioner er indiceret.
Treatment and prevention of flea infestation when concurrent prevention of heartworm disease and/or concurrent treatment of nematode infections is indicated.
Behandling og forebyggelse mod lopper, Ctenocephalides spp. i op til en måned efter en enkelt behandling.
Treatment and prevention of flea infestations caused by Ctenocephalides spp. for one month following a single administration.
Behandling og kontrol af gastrointestinale nematoder hos svin smittet med:
Treatment and control of gastro-intestinal nematodes in pigs infected with:
Behandling og metafylakse af enzootisk pneumoni hos svin forårsaget af følsomme stammer af Mycoplasma hyopneumoniae hos svin.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae in pigs.
Behandling og metafylakse af enzootisk pneumoni hos svin forårsaget af følsomme stammer af Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae in pigs.
Behandling og metafylakse af enzootisk pneumoni hos svin forårsaget af følsomme stammer af Mycoplasma hyopneumoniae.
Treatment and metaphylaxis of swine enzootic pneumonia caused by susceptible strains of Mycoplasma hyopneumoniae.
Behandling og metafylakse af luftvejsinfektioner forårsaget af Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumonia, Haemophilus parasuis og Bordetella bronchiseptica følsomme for tulathromycin.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Behandling og metafylakse af luftvejsinfektioner forårsaget af Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumonia, Haemophilus parasuis og Bordetella bronchiseptica følsomme for tulathromycin.
Treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Behandling og metafylakse af luftvejsinfektioner forårsaget af Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis og Bordetella bronchiseptica følsomme for tulathromycin.
Treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica sensitive to tulathromycin.
Behandling og metafylakse af luftvejsinfektioner hos kvæg (BRD) forårsaget af tulathromycinfølsomme Mannheimia haemolytica, Pasteurella multocida, Histophilus somni og Mycoplasma bovis.
Treatment and metaphylaxis of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis sensitive to tulathromycin.
Behandling og metafylakse af respirationsvejslidelser (BRD) hos kvæg i forbindelse med infektioner med Mannheimia haemolytica, Pasteurella multocida og Histophilus somni.
Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Behandling og metafylakse af svinedysenteri forårsaget af Brachyspira hyodysenteriae i besætninger, hvor sygdommen er blevet diagnosticeret.
Treatment and metaphylaxis of swine dysentery in herds, caused by Brachyspira hyodysenteriae, where the disease has been diagnosed.
Behandling og metafylakse af svinedysenteri forårsaget af Brachyspira hyodysenteriae i besætninger, hvor sygdommen er blevet diagnosticeret.
Treatment and metaphylaxis of swine dysentery, caused by Brachyspira hyodysenteriae in herds where the disease has been diagnosed.
behandling overvejes.
alternative antifungal treatment should be considered.
behandling sammen med strålebehandling (kombinationsfasen) først efterfulgt af behandling kun med Temozolomid Teva (monoterapi-fasen).
treatment together with radiotherapy (concomitant phase) first followed by treatment with only Temozolomide Teva (monotherapy phase).
behandling sammen med strålebehandling (konkomitant-fasen) først efterfulgt af behandling kun med Temodal (monoterapi-fasen)
treatment together with radiotherapy (concomitant phase) first followed by treatment with only Temodal (monotherapy phase).
behandling sammen med strålebehandling (konkomitant-fasen) først efterfulgt af behandling kun med Temomedac (monoterapi-fasen).
treatment together with radiotherapy (concomitant phase) first followed by treatment with only Temomedac (monotherapy phase).
behandling sammen med strålebehandling (konkomitant-fasen) først efterfulgt af behandling kun med Temozolomide HEXAL (monoterapi-fasen).
treatment together with radiotherapy (concomitant phase) first followed by treatment with only Temozolomide Hexal (monotherapy phase).
behandling sammen med strålebehandling (konkomitant-fasen) først efterfulgt af behandling kun med Temozolomide Sandoz (monoterapi-fasen)
treatment together with radiotherapy (concomitant phase) first followed by treatment with only Temozolomide Sandoz (monotherapy phase).
Behandling samtidigt med vardenafil bør kun initieres såfremt patienten er i stabil alfa-blokker-behandling.
Concomitant treatment with vardenafil should only be initiated if the patient has been stabilised on his alpha-blocker therapy.
Behandling skal fortsætte 1 gang om måneden indtil en måned efter myggesæsonen.
The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.
Behandling skal fortsætte regelmæssigt 1 gang om måneden indtil en måned efter myggesæsonen.
The treatment should continue at regular monthly intervals until 1 month after the last exposure to mosquitoes.
Behandling skal genoptages inden 2 uger ved tidligere dosis, hvis ANC >1,0 x 109/l og/eller trombocytter >50 x 109/l.
Treatment must be resumed within 2 weeks at prior dose if ANC
Behandling skal initieres af en læge med erfaring i diagnosticering og behandling af patienter med CML.
Therapy should be initiated by a physician experienced in the diagnosis and the treatment of patients with CML.
Behandling skal initieres og monitoreres under opsyn af en erfaren gastroenterolog/hepatolog eller i tilfælde af pædiatriske patienter en pædiatrisk gastroenterolog/hepatolog.
Treatment must be initiated and monitored by an experienced gastroenterologist/hepatologist or a paediatric gastroenterologist/hepatologist in the case of paediatric patients.
Behandling skal initieres og superviseres af læger med erfaring i endokrinologi eller intern medicin og med passende faciliteter til monitorering af biokemiske responser, da dosis skal justeres i forhold til patientens terapeutiske behov, baseret på normalisering af kortisolniveauet.
Treatment should be initiated and supervised by physicians experienced in endocrinology or internal medicine and having the appropriate facilities for monitoring of biochemical responses since the dose must be adjusted to meet the patient’s therapeutic need, based on the normalisation of cortisol levels.
Behandling skal initieres og superviseres af speciallæger med erfaring i diagnosticering og behandling af reumatoid artritis eller JIA.
Treatment should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of rheumatoid arthritis or JIA.
Behandling skal påbegyndes under supervision af en læge med erfaring i behandling af sygdommen.
Treatment should be initiated under supervision of a physician experienced in the treatment of the disease.
Behandling skal stoppes, hvis krampeanfald forekommer.
Treatment should be stopped if seizures occur.
Behandling Triumeq skal omgående ophøre ved mistanke om en overfølsomhedsreaktion, også selv om patienten er HLA-B*5701-allel-negativ.
Triumeq must be stopped without delay, even in the absence of the HLA-B*5701 allele, if an HSR is suspected.
Behandling ud over 12 uger skal nøje genovervejes hos patienter, som ikke responderer inden for denne tidsperiode.
Continued therapy beyond 12 weeks should be carefully reconsidered in a patient with no improvement within this time period.
Behandling ud over 16 uger bør overvejes nøje, hvis patienten ikke responderer inden for denne periode.
Continued therapy beyond 16 weeks should be carefully considered in a patient not responding within this time period.
Behandling ud over 16 uger skal nøje overvejes hos patienter, som ikke responderer inden for denne tidsperiode.
Continued therapy beyond 16 weeks should be carefully reconsidered in a patient not responding within this time period.
Behandling umiddelbart før eller samtidigt med vincristin kan øge Oncaspars toksicitet, hvilket øger risikoen for anafylaktiske reaktioner.
Immediately preceding or simultaneous treatment with vincristine can increase the toxicity of Oncaspar and increases the risk of anaphylactic reactions.
Behandling ved klinisk forværring af PAH
Management in case of clinical deterioration of PAH
Behandling ved overdosering bør følge medicinsk standardpraksis.
Treatment of overdose should follow standard medical practice.
Behandling vil reducere spredningen af Isospora infektion, men vil ikke have effekt mod symptomer hos dyr, der allerede er inficerede.
Treatment will reduce the spread of Isospora infection but will not be effective against symptoms in already infected animals.
Behandling*
Treatment
Behandling, n
Treatment, N
behandling, når lumacaftor/ivacaftor
of treatment when initiating lumacaftor/
Behandling, som anbefales i sygdommens svære stadier (f.eks epoprostenol), bør overvejes, hvis den kliniske tilstand forringes.
Therapy that is recommended at the severe stage of the disease (e.g. epoprostenol) should be considered if the clinical condition deteriorates.
Behandling:
Management
Behandling: behandlingsnaive: Viekirax uden ribavirin eller med ribavirin baseret på vægt i 12 uger og pegIFN + RBV-erfarne: Viekirax med ribavirin baseret på vægt i 12 uger
Treatment: treatment naïve: Viekirax without ribavirin or with weight-based ribavirin for 12 weeks pegIFN + RBV experienced: Viekirax with weight-based ribavirin for 12 weeks
Behandling: I tilfælde af overdosering bør der anvendes symptomatisk behandling.
Treatment: In the event of overdose, treatment should be symptomatic.
Behandling: INTELENCE over for placebo ud over et baggrundsregime bestående af darunavir/ritonavir (DRV/rtv), investigatorvalgte N(t)RTI-midler og valgfri enfuvirtid (ENF).
Treatment: INTELENCE vs. placebo, in addition to a background regimen including darunavir/ritonavir (DRV/rtv), investigator-selected N(t)RTIs and optional enfuvirtide (ENF).
Behandling: Viekirax og dasabuvir med ribavirin baseret på vægt i 12 eller 24 uger
Treatment: Viekirax and dasabuvir with weight-based ribavirin for 12 or 24 weeks
Behandling: Viekirax og dasabuvir med ribavirin-dosen fastsat efter investigators skøn i 24 uger
Treatment: Viekirax and dasabuvir with investigator chosen ribavirin dose for 24 weeks
Behandling: Viekirax og dasabuvir uden ribavirin eller med ribavirin baseret på vægt i 12 uger
Treatment: Viekirax and dasabuvir without ribavirin or with weight-based ribavirin for 12 weeks
behandlingb
treatmentb
Behandlingen af CMV-nethindebetændelse er nødvendig for at nedsætte risikoen for blindhed.
Treatment for CMV retinitis is necessary to reduce the potential for blindness.
Behandlingen af disse patienter bør forestås af læger med erfaring i behandling af patienter med hæmofili A eller med FVIII-inhibitorer.
The management of such patients should be directed by physicians with experience in the care of haemophilia A patients and those with factor VIII inhibitors.
Behandlingen af disse patienter bør ledes af en læge med erfaring i behandling af patienter med hæmofili og faktor VIII-inhibitorer.
The management of such patients should be directed by physicians with experience in the care of patients with haemophilia and factor VIII inhibitors.
Behandlingen af disse patienter bør ledes af en læge med erfaring i behandlingen af patienter med hæmofili og faktor VIII-inhibitorer.
Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.
Behandlingen af dyrkede humane hepatocytter med fampridin havde ringe eller ingen virkning på induktionen af CYP1A2-, CYP2B6-, CYP2C9-, CYP2C19-, CYP2E1- eller CYP3A4/5- enzymaktiviteter.
Treatment of cultured human hepatocytes with fampridine had little or no effect on induction of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2E1 or CYP3A4/5 enzyme activities.
Behandlingen af en akut overdosering af INCRELEX skal fokusere på at afhjælpe lavt blodsukker (hypoglykæmi).
Treatment of acute overdose of INCRELEX should be directed at reversing hypoglycaemia.
Behandlingen af formodede bivirkninger kan kræve midlertidig afbrydelse af behandlingen med temsirolimus og/eller dosisreduktion i henhold til retningslinjerne i nedenstående tabeller.
Management of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy according to the guidelines in the following tables.
Behandlingen af influenza med Ebilfumin skal påbegyndes senest to dage efter, at symptomerne har sat ind.
In the treatment of flu, Ebilfumin must be started within two days of the onset of symptoms.
Behandlingen af influenza med Tamiflu skal påbegyndes senest to dage efter, at symptomerne har sat ind.
In the treatment of flu, Tamiflu must be started within two days of the onset of symptoms.
Behandlingen af knogletab, der er forbundet med androgen deprivationsterapi (ADT)
Treatment of bone loss associated with androgen deprivation
Behandlingen af overdosering bør rettes mod opretholdelse af de livsvigtige funktioner.
Management of overdose should be directed at maintaining vital functions.
Behandlingen af patienterne fortsatte i 20 uger, når de var nået op på fuld dosis.
The patient’s treatment was continued for 20 weeks once they were taking their full dose.
Behandlingen af sådanne patienter bør forestås af læger med erfaring i hæmofilibehandling og faktor VIII-inhibitorer.
Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.
Behandlingen afbrydes hos patienter, som udvikler tegn på dekompenseret leversygdom.
Discontinue treatment in patients who develop evidence of hepatic decompensation.
behandlingen afbrydes i 1 dag eller mere i løbet af de første 2 uger af behandlingen.
treatment is interrupted for one day or more during the first 2 weeks of treatment.
behandlingen afbrydes i mere end 7 dage i løbet af uge 3 og 4 i behandlingen. behandlingen afbrydes i mere end 2 uger efter mindst 1 måneds behandling.
treatment is interrupted for more than 7 days during weeks 3 and 4 of treatment. treatment is interrupted for more than 2 weeks after at least 1 month of treatment.
Behandlingen afbrydes indtil kliniske objektive tegn og klinisk patologi er normaliseret.
Discontinue treatment until clinical signs and clinical pathology have normalised.
Behandlingen ansås for at have virket, hvis patienterne opnåede et virusindhold på under 50 hiv-1- RNA-kopier/ml efter 48 ugers behandling.
Patients who attained a viral load of less than 50 HIV-1 RNA copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Behandlingen begynder med en injektion i en vene af en dosis på 30 µg/kg
Treatment starts with an injection into a vein at a dose of 30 micrograms per kilogram
Behandlingen begynder med, at du først får et andet lægemiddel, der kaldes for G-CSF (granulocytkoloni-stimulerende faktor).
Mobilisation will be started by first giving you another medicine called G-CSF (granulocyte-colony stimulating factor).
Behandlingen består af ophør med MabCampath og symptomatisk behandling.
Treatment consists of discontinuation of MabCampath and supportive therapy.
Behandlingen består af otte infusioner af en sprøjte med 24 timers interval.
Treatment consists of eight infusions of one syringe every 24 hours.
Behandlingen blev anset for at have virket (patienten havde responderet), hvis virusbelastningen i patientens blod var mindre end 50 HIV-1-RNA-kopier/ml.
The infection was considered to have responded to treatment if the viral load in the patient’s blood was less than 50 of HIV-1 RNA copies/ml.
Behandlingen blev defineret som "vellykket", når der kunne observeres knoglevæv mellem de påvirkede hvirvler på røntgenbilleder, og patienten havde vist fremskridt i funktionsevne, uden behov for yderligere behandling af rygsøjlen og uden alvorlige bivirkninger eller forværring af symptomer på grund af tryk på nerverne.
Treatment was defined as ‘successful’ when bone could be seen between the affected vertebrae on X-rays, and the patient had shown improvement in disability, with no need for further treatment of the spine, no serious side effects and no worsening of the symptoms caused by pressure on the nerves.
Behandlingen blev seponeret hos 5 patienter med perifer neuropati på teriflunomid 14 mg.
Treatment was discontinued in 5 patients with peripheral neuropathy on teriflunomide 14 mg.
Behandlingen blev seponeret på grund af behandlingsrelaterede uønskede hændelser hos 5,7% af de ospemifen-behandlede kvinder og hos 1,8% af de placebo-behandlede kvinder.
Therapy was discontinued due to treatment-related adverse events in 5.7% of ospemifene-treated women and 1.8% of placebo-treated women.
Behandlingen bør afbrydes efter 10 dage, hvis der ikke er set en effekt.
Treatment should be discontinued after 10 days if no clinical improvement is apparent.
Behandlingen bør afbrydes hos patienter, som udvikler QTc-interval over 500 msek målt på mindst 2 forskellige EKG’er, indtil QTc-intervallet er under 481 msek eller tilbage til baseline-niveau, hvis QTc-intervallet er over eller lig med 481 msek; genstart Tagrisso- behandlingen med en reduceret dosis som beskrevet i Tabel 1.
Treatment should be withheld in patients who develop a QTc interval greater than 500 msec on at least 2 separate ECGs until the QTc interval is less than 481 msec or recovery to baseline if the QTc interval is greater than or equal to 481 msec, then resume TAGRISSO at a reduced dose as described in Table 1.
Behandlingen bør afbrydes i tilfælde af:
Treatment should be discontinued in case of:
Behandlingen bør afbrydes senest efter 10 dage, hvis der ikke ses klinisk bedring.
Treatment should be discontinued after 10 days after the latest if no clinical improvement is apparent.
Behandlingen bør afbrydes, hvis en patient fortsat oplever nogen af disse reaktioner ved 20 mg/m2.
The treatment should be discontinued if a patient continues to experience any of these reactions at 20 mg/m2.
Behandlingen bør altid påbegyndes i den første uge af det månedlige blødningsforløb (menstruationscyklussen).
Treatment should always be started during the first week of the menstrual cycle (period bleeding).
Behandlingen bør bestå af generelt understøttende tiltag, inklusive monitorering af vitale tegn og ekg samt observation af patientens kliniske status.
Treatment should consist of general supportive measures including monitoring of vital signs and ECG as well as observation of the patient’s clinical status.